Vandana Singh

Vandana Singh

Benzinga Editor

About
Vandana Singh, MBA Finance is an Editor of the Benzinga Breaking News. Vandana has been covering the healthcare sector for over 10 years, including providing support services to renowned investment banks.
Philip Morris' Ambitious Plans for Heated Tobacco Gains Traction Among Analysts and Investors
Philip Morris sets sights on U.S. heated tobacco market with IQOS launch. Analysts optimistic despite vaping competition. Ambitious goal: 10% market share within 5 years. Potential to convert 2.8 million smokers. Regulatory challenges ahead.
AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
Discover the latest on AstraZeneca's Covid vaccine lawsuit. Allegations of serious side effects, including fatalities and brain injuries, spark legal battles. Learn about the controversy and potential ramifications.
Boeing To Raise $10B Via Bond Sale Amid Credit Rating Downgrade - Will Investors Show Confidence?
Boeing plans a $10 billion bond sale amid financial challenges. Moody's downgrade reflects strain, but CFO emphasizes commitment to stability. Long-term bonds yield 2.25% higher than Treasuries.
Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?
Annovis Bio faces setbacks in Phase 2/3 Alzheimer's study, revealing minimal change in patients' conditions. Despite slight improvements in mild cases, results show no significant difference in treatment groups.
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds despite setbacks.
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug discovery, commercial platforms, and a pipeline of cancer drugs including QINLOCK. Acquisition expected to close Q3 2024.
FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder
FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care.
Double Good News For AstraZeneca's Breast Cancer Drugs
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.
Philips Reaches $1.1B Settlement On US Sleep Apnea Devices' Claims, Backs Annual Guidance
Philips settles $1.1 billion in Respironics ventilator recall lawsuit. Updates on Philips' Q1 performance and 2024 guidance. PHG shares surge 36.9% in premarket trading.
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent infringement in mRNA technology.
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of $3,500 yearly.
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers.
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.
Why Is HCA Healthcare Stock Trading Lower On Friday?
HCA Healthcare's first-quarter results, surpassing revenue and EPS expectations. CEO Sam Hazen emphasizes sustained momentum and volume growth.
Avantor's Conservative Guidance Is Realistic Post Q1 Earnings Performance: Analyst
Avantor reports Q1 net sales of $1.68 billion, down 5.6% Y/Y. Adjusted EBITDA stands at $283M, with EPS of $0.22, beating consensus.
Centene's First-Quarter Surge: Sales Soar To $40.41B, Exceeding Expectations: What's Next For The Healthcare Company?
Centene outperforms expectations with $40.41 billion in Q1 sales, driven by robust growth in premium revenues and steady membership. Raises full-year guidance amid strong momentum.
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.
Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sales growth. The acquisition of Invitae is expected to bolster Labcorp's specialty testing capabilities.
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.